MedCAC Supports Some PGx Test Regimens, But Calls For Overall Better Data
This article was originally published in The Gray Sheet
Executive Summary
There is enough strong evidence to show that a select few pharmacogenomic (PGx) tests can be applied in a manner that positively affects patient outcomes, members of a CMS advisory panel concluded Jan. 27